Pollen Allergy Pipeline Analysis Report 2026

Report Coverage

The Pollen Allergy Pipeline Analysis Report by Expert Market Research gives comprehensive insights into pollen allergy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pollen allergy. The pollen allergy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pollen allergy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pollen allergy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pollen allergy.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Pollen Allergy Pipeline Outlook

Pollen allergy is an immunoglobulin E-mediated allergic condition triggered when the immune system overreacts to airborne pollen from trees, grasses, or weeds. Exposure causes the release of histamine and other inflammatory mediators, resulting in allergic rhinitis, sneezing, nasal congestion, itchy eyes, and other seasonal allergy symptoms that can significantly affect daily activities and quality of life.

Pollen allergy treatment includes allergen avoidance, antihistamines, intranasal corticosteroids, decongestants, and leukotriene receptor antagonists. For persistent or moderate-to-severe cases, allergen immunotherapy provides long-term immune tolerance by targeting the underlying allergic response. In July 2025, ALK-Abelló received approval for ITULAZAX® (Betula verrucosa, 12 Standardized Quality-Bet), the first immunotherapy tablet for birch tree pollen allergy. The therapy promotes long-term immune tolerance, reduces allergic rhinitis symptoms, and strengthens the pipeline.

Pollen Allergy Epidemiology

The pipeline is gaining momentum as the growing incidence of pollen allergy continues to increase the demand for innovative therapies. According to the Asthma and Allergy Foundation of America, more than 106 million people in the United States are affected by allergies and/or asthma, with pollen being a major seasonal trigger. Additionally, according to Bhargavi S., Picardo et al. (2024), 10% to 40% of the Indian population experiences pollen allergy, while pollens account for 20% of allergy cases in Bengaluru. This expanding epidemiology supports continued drug development and pipeline research for improved treatment options.

Pollen Allergy – Pipeline Therapeutic Assessment

Pollen Allergy Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 59%, covers a major share of the total pollen allergy clinical trials, driven by a strong pipeline focused on optimizing efficacy, expanding patient populations, and advancing clinical validation, followed by phase III at 41%, supported by late-stage candidates aimed at regulatory progress, commercialization readiness, and improved treatment availability. Together, these development phases are expected to accelerate innovation and support sustained growth in the Pollen Allergy market.

Pollen Allergy Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the pollen allergy pipeline analysis include small molecules, monoclonal antibodies, peptides, vaccines, and recombinant proteins. The pollen allergy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pollen allergy. Grass pollen allergen immunotherapy is a prominent drug class in the pollen allergy drug pipeline, driven by the development of disease-modifying treatments. For instance, Grassmuno (Grass MATA MPL) is under evaluation and regulatory expansion for grass pollen allergy. This subcutaneous immunotherapy (SCIT) targets long-term immune tolerance by modulating allergen-specific immune responses, reducing allergic rhinitis symptoms, medication use, and seasonal disease burden.

Pollen Allergy Clinical Trials – Key Players

The EMR report for the pollen allergy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed pollen allergy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in pollen allergy clinical trials:

• Regeneron Pharmaceuticals
• Desentum Oy
• Inmunotek S.L.
• Shanghai Mabgeek Biotech. Co. Ltd.
• Prime Gene Therapeutics Co., Ltd.
• Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• Akeso
• Chengdu Kangnuoxing Biopharma, Inc.
• Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Pollen Allergy – Emerging Drugs Profile

Key Questions Answered in the Pollen Allergy Pipeline Insight Report

• Which companies/institutions are leading the pollen allergy drug development?
• Which company is leading the pollen allergy pipeline development activities?
• What is the current pollen allergy commercial assessment?
• What are the opportunities and challenges present in the pollen allergy pipeline landscape?
• What is the efficacy and safety profile of pollen allergy pipeline drugs?
• Which company is conducting major trials for pollen allergy drugs?
• Which companies/institutions are involved in pollen allergy collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in pollen allergy?

Reasons To Buy This Report

The pollen allergy pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for pollen allergy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pollen allergy collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

Pollen Allergy Epidemiology Forecast

Allergy Treatment Market